-
公开(公告)号:US11648305B2
公开(公告)日:2023-05-16
申请号:US16909040
申请日:2020-06-23
申请人: Altimmune UK Limited
IPC分类号: A61K39/145 , A61K39/00 , A61K39/385 , A61K47/64 , A61K39/12 , C12N7/00
CPC分类号: A61K39/145 , A61K39/00 , A61K39/12 , A61K39/385 , A61K47/646 , C12N7/00 , A61K2039/54 , A61K2039/541 , A61K2039/542 , A61K2039/544 , A61K2039/60 , A61K2039/6093 , C12N2760/16034 , C12N2760/16122 , C12N2760/16134 , Y02A50/30
摘要: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
-
公开(公告)号:US10729759B2
公开(公告)日:2020-08-04
申请号:US14807606
申请日:2015-07-23
申请人: ALTIMMUNE UK LIMITED
IPC分类号: A61K38/00 , A61K38/16 , A61K38/10 , A61K9/00 , A61K39/12 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , A61K39/145 , A61K39/00 , A61K39/385 , A61K47/64 , C12N7/00
摘要: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
-
公开(公告)号:US20210038710A1
公开(公告)日:2021-02-11
申请号:US16909040
申请日:2020-06-23
申请人: Altimmune UK Limited
IPC分类号: A61K39/145 , A61K39/00 , A61K39/385 , A61K47/64 , A61K39/12 , C12N7/00
摘要: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
-
-